Expanding Biosimilars And Specialty Pipelines Will Harness Secular Trends
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 11 Analysts
Published
13 Jul 25
Updated
08 Aug 25
AnalystHighTarget's Fair Value
₹2,934.00
30.3% undervalued intrinsic discount08 Aug
₹2,044.60
1Y
37.1%7D
-0.9%